Christopher Mengler

This profile gathers the share dealings of Christopher Mengler across 2 companies, led by Impax Laboratories, LLC and Barr Pharmaceuticals Inc. Between 3 January 2006 and 5 November 2010, the trades on record add up to 21 filings.

On the open market, the record shows 5 purchases worth €101k and 6 sales worth €1.0M. Sales outweigh purchases by €923k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 6 share grants and 4 option exercises. In 2010 alone, the filings show 1 purchase and 3 sales.

A typical purchase (the median) is worth €21k.

The newest entry dates from 9 November 2010: an open-market sale of €101k, in Impax Laboratories, LLC. The latest purchase dates back some time: it was published 5,933 days ago, on 12 August 2010. Typically, a trade is published a median of 1 day after it takes place. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.